Sensorion, a biotech working on therapies for inner ear diseases, said today that it inked a deal with Cochlear Ltd (ASX:COH) to study combination therapies for patients with cochlear implants. According to the deal, the companies will combine Sensorion’s SENS-401 compound with cochlear implants in preclinical studies starting next year. The drug-device therapies could be […]